摘要
目的观察联合血管紧张素Ⅱ受体拮抗剂替米沙坦治疗慢性充血性心力衰竭(CHF)的临床疗效及安全性。方法选择慢性充血性心力衰竭患者34例,根据治疗情况随机分成两组,常规治疗组14例给予内科常规抗心力衰竭治疗,试验组20例在常规治疗的基础上加用替米沙坦治疗。治疗前后观察静息心率(HR)、收缩压(SBP)、舒张压(DBP)、心功能级别、左室舒张末内径(LVEDD)、左室射血分数(LVEF)及心脏指数(CI)。结果两组患者的各项指标在治疗后均较治疗前有明显改善,但试验组较常规治疗组改善更为显著,其临床疗效优于常规治疗组(P<0.05)。结论在常规抗心衰治疗基础上加用替米沙坦可明显改善患者心功能,是一种安全有效的临床治疗方法。
Objective To study the clinical effects of Telmisartan for congestive heart failure. Methods Thirty - four patients with congestive heart failure （cardiac function NYHA Ⅱ - Ⅲ class） were divided randomly into two groups： treatment group （20 cases） and control group （ 14 cases）. The routine therapy for the two groups was same, the only difference was that for the treatment group, Telmisartan was added. The observable factors such as heart rate, systolic blood pressure, diastolic blood pressure, heart functional class, left ventricle end -diastole diameter, left ventricle ejection fraction, cardiac index and so on, were collected for both groups. Results After treatment, the observable factors in both groups were improved magnificently. However, the improvement in the treatment group was markedly superior to the control group （ P 〈 0. 05）. Conclusion Telmisartan is an effective medicine for congestive heart failure on the basis of routine therapy.
出处
《中国医学创新》
CAS
2009年第24期11-13,共3页
Medical Innovation of China
关键词
替米沙坦
慢性充血性心力衰竭
临床疗效
Telmisartan
Chronic congestive heart failure
Clinical effects
